1	Comparison of NAFLD, MAFLD, MASLD and pure-MASLD characteristics and mortality
2	outcomes in United States adults
3	
4	Running title: Comparison of NAFLD, MAFLD, MASLD and pure-MASLD
5	
6	Rui Song ^{1#} , Zhao Li ^{2#} , Yingzhi Zhang ^{1#} , Jiahe Tan ³ , Zhiwei Chen ^{1*}
7	
8	¹ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute
9	for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital of
10	Chongqing Medical University, Chongqing, China
11	² Department of Gastroenterology, the Seventh People's Hospital of Chongqing, Chongqing,
12	China.
13	³ Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University,
14	Chongqing, China.
15	
16	# These authors contribute equally to this work.
17	* Corresponding author. Address: Institute for Viral Hepatitis, The Key Laboratory of Molecular
18	Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of
19	Chongqing Medical University, 74 Linjiang Road, Yuzhong District, Chongqing 400010, China.
20	E-mail addresses: zhiwei_chen@cqmu.edu.cn.
21	

²² Key words: NAFLD; MAFLD; MASLD; pure-MASLD; mortality; NHANES III NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24	Background: After metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic
25	fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-
26	associated steatotic liver disease (MASLD). However, the distinctions in characteristics and
27	mortality outcomes between NAFLD, MAFLD, MASLD, and pure-MASLD are still unclear.
28	Methods: We analyzed data from 6,708 participants in the third National Health and Nutrition
29	Examination Surveys 1988-1994 of United States (US) and their linked mortality through 2019.
30	NAFLD, MAFLD, MASLD and pure MASLD were defined based on respective criteria. Survey-
31	weight adjusted multivariable Cox proportional model was used to study the mortality of the four
32	terms.
33	Results: The overall prevalence of NAFLD, MAFLD, MASLD and pure-MASLD was 28.9%
34	(n=1,937), 26.1% (n=1,753), 29.0% (n=1,948), and 26.0% (n=1,741), respectively. For NAFLD,
35	81.3%, 89.9% and 89.9% fulfilled the criteria for MAFLD, MASLD and pure MASLD. For
36	MAFLD, all were classified into the MASLD, and 89.8% were met the criteria of pure-MASLD.
37	During a median follow-up of 27 years, both individuals with MAFLD and MASLD had higher
38	risk of all-cause mortality (adjusted hazard ratio [aHR]: 1.21, 95% CI 1.09-1.352; and 1.11, 1.00-
39	1.23, respectively). NAFLD and pure-MASLD were not associated with all-cause mortality. All
40	the four terms were associated with increased all-cause mortality in individuals with advanced
41	fibrosis (aHR: 1.66-1.83). Subgroup analyses showed that higher risk of all-cause mortality of
42	NAFLD, MAFLD, MASLD and pure-MASLD were observed in female, age 41-55 years, non-
43	Hispanic white, and never smoking subgroups when focused on moderate-severe hepatic steatosis.
44	Conclusions: In this US population-based study, MASLD could identify more individuals with

45 all-cause mortality risk than MAFLD, meanwhile, NAFLD and pure-MASLD had similar

- 46 characteristics and mortality outcomes.

67 Introduction

68	Non-alcoholic fatty liver disease (NAFLD) has become one of the leading causes of chronic liver
69	disease in the world, which can progress into hepatic fibrosis and end-stage liver diseases
70	eventually ¹ . Most recently, a new term metabolic dysfunction-associated steatotic liver disease
71	(MASLD) was recommended to replace NAFLD and metabolic dysfunction-associated fatty liver
72	disease (MAFLD) by the Delphi consensus ² , which involved a change in not only the
73	nomenclature but also the definition. MASLD, as the umbrella term, comprised broader metabolic
74	risk factors, and can co-exist with other chronic liver diseases. To better distinguish the etiologies,
75	MASLD was further classed into pure-MASLD, MetALD or MASLD with other combination
76	etiology ² . Since the new term of MASLD was proposed, it is concern whether the new definition
77	of MASLD will impact the old NAFLD data using, biomarker discovery or the nature history.
78	Moreover, some are worried that this new term will add the difficulty and confusion to people due
79	to frequent changes in nomenclature of NAFLD ³⁴ . Hence, it is urgent for us to clarify the relation
80	characteristic and mortality outcomes of these terms in clinical practice.
81	Several studies found that NAFLD was highly in accordance with MASLD in clinical features ⁵⁻⁸ ,
82	however, these studies were limited by the use of small or specific patient populations. A recent
83	study reported similar prevalence and risk factors of NAFLD, MAFLD and MASLD in a large
84	Brazilian cohort, but the long-term mortalities among these terms are not assessed ⁹ . Some studies
85	evaluated the mortality outcomes of MASLD and/or MAFLD, but showed inconsistent results 10-
86	¹² . Meanwhile, the comparison of NAFLD, MAFLD, MASLD and pure-MASLD clinical
87	outcomes was not performed in these previous studies. Therefore, the similarities and differences
88	of characteristic and long-term mortality among individuals with NAFLD, MAFLD, MASLD and

89	pure-MASLD	in a general	population	are still	unknown.
----	------------	--------------	------------	-----------	----------

90	In this study,	we conducted a co	mprehensive anal	ysis in 6708 n	onpregnant adult	participants from
	<u> </u>			2		

- 91 the Third National Health and Nutrition Examination Survey 1988-1994 (NHANES III). By using
- 92 the nationally representative sample of United States (US) adults, we compared the relationship
- and clinical features among NAFLD, MAFLD, MASLD and pure-MASLD, and assessed the
- 94 association of the four terms on all-cause and cause-specific mortality.
- 95

96 Materials and methods

97 Study design and participants

- 98 The NHANES III is a national survey program to assess health and nutritional status obtained
- 99 using a complex, stratified, clustered multi-staged probability sampling design to acquire a
- 100 nationally representative sample of US populations ¹³. This survey included demographic data,
- 101 health-related questionnaires, physical examinations, laboratory tests, and hepatic/gallbladder
- 102 ultrasound in 13,588 nonpregnant adults (20-74 years).
- 103 First, we excluded 1,261 individuals with missing data on mortality status, body mass index, waist
- 104 circumference, and laboratory tests, including high-density lipoprotein (HDL)-cholesterol,
- triglycerides, hemoglobin A1c and fasting glucose. Because of focusing on hepatic steatosis in this
- study, not steatohepatitis, we then excluded 1,223 individuals with elevated liver enzymes levels.
- 107 To accurately assess the effect of alcohol intake on SLD, we further excluded 4,228 individuals
- 108 with missing data on alcohol assumption. In addition, we also excluded 258 individuals with HCV
- and/or HBV infection, and those with a BMI $< 18.5 \text{ kg/m}^2$, given the potential confounding effect
- 110 of viral hepatitis and undernutrition. Lastly, 6,708 individuals were included for the main analysis

- in this study (Figure. S1). There is no significant difference of demographic and clinical
- 112 characteristics among populations during selection process (Table S1). All individuals signed
- 113 informed consent to participate in NHANES III.
- 114 Data collection
- 115 For each participant of NHANES III, the information about demographic indexes (such as sex,
- age, ethnicity, education, marital status, smoking, alcohol consumption, physical activity,
- underlying diseases, and drug use), anthropometric indexes (such as body mass index (BMI),
- 118 waist circumference, and blood pressure), and laboratory tests (such as alanine aminotransferase,
- aspartate aminotransferase, HDL-cholesterol, fasting glucose) were collected. The definitions,
- such as hypertension, diabetes, smoking status, alcohol consumption, sedentary behavior, were
- 121 provided in the supplementary materials.

122 Definition of NAFLD, MAFLD, MASLD, pure-MASLD and advanced fibrosis

123 In NHANES III, the ultrasonographic assessments were reported as normal vs. mild, moderate, or

severe hepatic steatosis ¹⁴. We defined steatosis liver diseases (SLD) as mild to severe hepatic

- steatosis without increased liver enzymes levels in this study. NAFLD was defined as the presence
- of SLD without excessive alcohol consumption (≥ 20 g/d for females and ≥ 30 g/d for males)
- 127 and/or other liver diseases (such as viral hepatitis)¹⁵. MAFLD was defined as the presence of SLD
- 128 with metabolic dysfunction, which comprises either overweight or obese (BMI $\geq 25 \text{ kg/m}^2$),
- diabetes mellitus, or a combination of at least 2 of the 7 metabolic risk abnormalities ¹⁶. MASLD
- 130 was defined as the presence of SLD combined with at least 1 of the 5 cardiometabolic adult
- 131 criteria². Pure-MASLD was defined as the presence of MASLD without excessive alcohol
- 132 consumption and other combination etiologies ². MetALD was defined as the presence of MASLD

133	with higher alcohol	consumption leve	s (20 to 50 g/	/d for females	and 30 to 60 g/d f	for males) 2 .
-----	---------------------	------------------	----------------	----------------	--------------------	-------------------

- 134 This detail definitions of MAFLD and MASLD were showed in the supplementary materials.
- 135 To give an insight into the similarities and differences between the four terms, individuals were
- 136 further classified into different groups. For example, we defined NAFLD+ as individuals who met
- 137 the definition of NAFLD, and NAFLD- was defined as individuals who didn't meet NAFLD
- 138 definition. Likewise, NAFLD+/MAFLD-/MASLD-/pure-MASLD+ means an individual who met

both NAFLD and pure-MASLD definitions but not the definitions of MAFLD and MASLD.

- 140 Individuals without hepatic steatosis were referred to as a group with no hepatic steatosis.
- 141 We using the NAFLD fibrosis score (NFS) to evaluate advanced fibrosis of individual with SLD
- 142 ¹⁷. In detail, high (NFS >0.676), intermediate (NFS 0.676 to -1.455) and low probability for
- advanced fibrosis (NFS <-1.455) were defined.

144 All-cause and cause-specific mortality

- 145 The mortality data of adults in the NHANES III was passively follow-up and obtained from the
- 146 National Death Index, which contained complete data until December 31, 2019¹⁸. The definition
- 147 of all-cause mortality and cause-specific (cardiovascular disease and cancer) mortalities were
- showed in a previous study ¹⁹, and detailed information was presented in the supplementary
- 149 materials. Moreover, we calculated the follow-up time (month) from the date of interview to the
- 150 date of death or the end of the follow-up period.

151 Statistical analysis

- 152 The results of the baseline characteristics are expressed as median and interquartile range (IQR)
- 153 for continuous variables and unweighted frequency counts and weighted percentage for
- 154 categorical variables. We compared baseline characteristics using the Kruskal-Wallis test for

155	continuous variables and the chi-square test for categorical variables. Cox proportional hazards
156	regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for deaths
157	from all-causes, cardiovascular disease and cancer. To avoid an overadjustment bias in the
158	multivariable analysis ²⁰ , we discarded the related variables which have presented in the definition
159	of NAFLD, MAFLD and MASLD. We used two models with progressive degrees of adjustment:
160	model 1 adjusted for age, sex, and ethnicity; model 2 further adjusted for education, marital status,
161	smoking status, and sedentary lifestyle.
162	For sensitivity analysis, first, we added participants with hepatitis B, hepatitis C, or $BMI < 18.5$
163	kg/m ² into the entire population. Second, to assess the effect of varying degrees of SLD, we
164	carried out another sensitivity analysis comparing the group with no hepatic steatosis against those
165	with moderate- severe hepatic steatosis (that is, excluding those with mild steatosis from
166	individuals with SLD).
167	Lastly, we evaluated the association of NAFLD, MAFLD, MASLD and pure-MASLD with all-
168	cause mortality for subgroups defined by age, sex, ethnicity, BMI, diabetes, hypertension, and
169	smoking status. All analyses were performed with R (version 4.3.0; R Foundation for Statistical
170	Computing, Vienna, Austria), using the survey package to account for the sampling weights and

- 171 the complex survey design in the NHANES III.
- 172
- 173 Results

174 Characteristics of NAFLD, MAFLD, MASLD and pure-MASLD

175 After included individuals with available alcohol consumption and liver ultrasound data and

176 excluded individuals with increased liver enzymes levels or viral hepatitis etc., a total of 6708

177	participants from NHANES III were eligible for the final analysis (Figure. S1). The overall
178	prevalence of SLD, NAFLD, MAFLD, MASLD and pure-MASLD was 32.3% (n=2,164), 28.9%
179	(n=1,937), 26.1% (n=1,753), 29.0% (n=1948), and 26.0% (n=1,741), respectively (Figure 1).
180	Compared no hepatic steatosis group, older, less educated, obese, sedentary, and more coexisting
181	metabolic risk factors were observed in SLD group. Among NAFLD, MAFLD, MASLD and pure-
182	MASLD groups, individuals with MAFLD were more likely to be older, male, higher BMI and
183	waist circumference, higher alcohol intake, hypertension, and diabetes. (Table S2)
184	Further classified into different combinations of the 2,164 SLD individuals, six groups were
185	generated (NAFLD+/MAFLD+/MASLD+/pure-MASLD+, NAFLD+/MAFLD-/MASLD+/pure-
186	MASLD+, NAFLD-/MAFLD+/MASLD+/pure-MASLD-, NAFLD+/MAFLD-/MASLD-/pure-
187	MASLD-, NAFLD-/MAFLD-/MASLD+/pure-MASLD-, and NAFLD-/MAFLD-/MASLD-/pure-
188	MASLD-; Figure 1). As shown in Figure 1, most individuals with SLD were classified into
189	NAFLD+/MAFLD+/MASLD+/pure-MASLD+ (72.8%), followed by NAFLD+/MAFLD-
190	/MASLD-/pure-MASLD- (9.1%), NAFLD-/MAFLD+/MASLD+/pure-MASLD- (8.2%),
191	NAFLD+/MAFLD-/MASLD+/pure-MASLD+ (7.7%), NAFLD-/MAFLD-/MASLD+/pure-
192	MASLD- (1.3%), and NAFLD-/MAFLD-/MASLD-/pure-MASLD- (0.9%). For individuals with
193	NAFLD, 89.9% individuals were in accordance with MASLD and pure-MASLD, and 81.3%
194	individuals were in accordance with MAFLD. For individuals with MAFLD, 89.8% individuals
195	were in accordance with NAFLD and pure-MASLD, and 100% individuals in accordance with
196	MASLD. For individuals with MASLD, 89.4% individuals were in accordance with NAFLD and
197	pure-MASLD, and 90.0% individuals were in accordance with MAFLD. For individuals with
198	pure-MASLD, 100% individuals were in accordance with NAFLD and MASLD, and 90.5%

199 i	individuals were	in accordance with	MAFLD. The	baseline chara	acteristics of different
-------	------------------	--------------------	------------	----------------	--------------------------

- 200 combinations of SLD individuals were presented in Table 1. Similarly, older, obese, hypertension,
- 201 diabetes, and more metabolic risk factors were more presented in individuals with MAFLD+. In
- addition, men, and higher alcohol intake were more observed in individuals with NAFLD-.
- 203 Individuals with NAFLD+MAFLD- were more likely to be younger, female, lower BMI and waist
- 204 circumference, and lower metabolic risk factors.

205 All-cause and cause-specific mortality of NAFLD, MAFLD, MASLD and pure-MASLD

- 206 During the median follow-up of 27.0 (interquartile range: 24.6-28.9) years, the cumulative
- 207 mortality from all causes was 30.7% (2,061 deaths). For cause-specific mortality, cardiovascular
- disease was 537 deaths (8.0%), and cancer was 523 deaths (7.8%). In total, individuals with SLD
- 209 had a 1.12-fold higher all-cause mortality than those without SLD after adjustment for
- sociodemographic characteristics and lifestyle risk factors (model 2: adjusted HR (aHR): 1.12,
- 211 95% CI 1.00-1.25, Table 2). In detail, individuals with MAFLD showed a higher all-cause
- 212 mortality than those without MAFLD in multivariable model 2 (aHR: 1.21, 95% CI 1.09-1.35).
- 213 Similar result was also observed in MASLD individuals (aHR: 1.11, 95% CI 1.00-1.23). But the
- 214 increased risks of all-cause mortality were not presented in individuals with NAFLD or pure-
- 215 MASLD (aHR: 1.07, 95% CI 0.95-1.20; aHR: 1.07, 95% CI 0.96-1.19, respectively). (Table 2)
- After stratified by etiology of MASLD, we found that only MASLD with ALD (>50 g/d for
- females and >60 g/d for males) was associated with increased all-cause mortality compared with
- individuals with no hepatic steatosis (aHR: 2.10, 95% CI 1.22-3.60). Individuals with MetALD
- were not associated with all-cause mortality (aHR:1.17, 95% CI 0.84-1.64). (Table S3)
- 220 To further clarify the all-cause mortality among NAFLD, MAFLD, MASLD and pure-MASLD,

221	we classified SLD	individuals	into six	groups as	mentioned	above. As	shown in	Table 2.
		mar i addenio	meo om	SIG ab ab	memoried			10010 2,

- 222 individuals with NAFLD-/MAFLD+/MASLD+/pure-MASLD- had the highest risk of all-cause
- 223 mortality in multivariable model 2 (aHR: 1.34, 95% CI 1.02-1.77), followed by those with
- 224 NAFLD+/MAFLD+/MASLD+/pure-MASLD+ (aHR: 1.17, 95% CI 1.05-1.30). Unexpectedly,
- 225 individuals with NAFLD+/MAFLD-/MASLD+/pure-MASLD+ showed a lower risk of all-cause
- 226 mortality compared with individuals with no hepatic steatosis (aHR: 0.42, 95% CI 0.24-0.73). The
- rest of groups were not associated with all-cause mortality.
- 228 In subgroup analyses, MAFLD was associated with increased all-cause mortality in female,
- age >40 years, non-Hispanic white, BMI 18.5-24.9 kg/m², without diabetes and current smoking
- subgroups (aHR: 1.16-1.57, Figure 2A). For MASLD, similar results were only observed in age
- 41-55 years and non-Hispanic white subgroups. Pure-MASLD was only associated with a higher
- risk of all-cause mortality in age 41-55 years subgroup. And NAFLD was not associated with all-
- cause mortality in any subgroups. (Figure 2A)
- 234 When the analysis was restricted to cause-specific mortality, all the four terms and their
- 235 combinations were not showed a significant association with cardiovascular mortality or cancer
- 236 mortality (Table 3). But one combination was excepted, that is, individuals with
- 237 NAFLD+/MAFLD-/MASLD+/pure-MASLD+ showed both lower risk of cardiovascular mortality
- and cancer mortality (aHR: 0.17, 95% CI 0.03-0.83; aHR: 0.22, 95% CI 0.07-0.64, respectively).
- Lastly, we evaluated the effect of fibrosis on the all-cause mortality among NAFLD, MAFLD,
- 240 MASLD and pure-MASLD. As shown in Table 4, compared to low NFS score group, all the four
- terms showed increased risk of all-cause mortality irrespective in intermediate NFS score group or
- high NFS score group, which was larger in high NFS score group (intermediate NFS: aHR: 1.27-

243 1.53; high NFS: aHR: 1.66-1.83, respectively).

244 Sensitivity analyses of NAFLD, MAFLD, MASLD and pure-MASLD

- 245 Firstly, we want to know if other etiologies of SLD will affect the clinical outcomes. After added
- 246 individuals with other confounders (viral hepatitis and low BMI) to the entire population, similar
- findings of mortality outcomes were observed (Table S4-7). And then we wonder whether the
- extent of hepatic steatosis may have an influence on the mortality. After classified into three
- 249 groups (mild, moderate, and severe) of SLD according to the ultrasound results in NHANES III,
- 250 we found individuals with moderate and severe SLD were significantly associated with increased
- 251 all-cause mortality, and had similar effect (aHR: 1.21, 95% CI 1.06-1.39; aHR: 1.22, 95% CI 1.03-
- 252 1.45, respectively; Table S8). Hence, we conducted another sensitivity analysis excluding the mild
- 253 hepatic steatosis from SLD (that is, SLD were redefined as those with moderate-severe hepatic
- steatosis). Notably, in this scenario, not only MAFLD and MASLD were associated with increased
- all-cause mortality (aHR: 1.25, 95% CI 1.13-1.39; aHR: 1.24, 95% CI 1.12-1.38, respectively),
- 256 but also NAFLD and pure-MASLD did (aHR: 1.16, 95% CI 1.04-1.30; aHR: 1.18, 95% CI 1.05-
- 257 1.33, respectively; Table 5). Regarding the different of combinations, the results of
- 258 NAFLD+/MAFLD+/MASLD+/pure-MASLD+ group and NAFLD-/MAFLD+/MASLD+/pure-
- 259 MASLD- group were in line with our previous findings (aHR: 1.23, 95% CI 1.10-1.38; aHR: 1.39,
- 260 95% CI 1.06-1.83, respectively). However, the lower risk of all-cause mortality of
- 261 NAFLD+/MAFLD-/MASLD+/pure-MASLD+ group in previous was disappeared in this
- sensitivity analysis, instead of the NAFLD-/MAFLD-/MASLD+/pure-MASLD- group had a
- higher risk of all-cause mortality (aHR: 2.65, 95% CI 1.70-4.12). (Table 5) Compared to no
- hepatic steatosis, individuals with MetALD had a higher risk of all-cause mortality (aHR: 1.41,

- 265 95% CI 1.02-1.94), whereas MASLD with ALD was not associated with all-cause mortality (aHR:
- 266 1.95, 95% CI 0.97-3.91, P=0.06; Table S9).
- 267 In addition, for the cause-specific mortality in different terms of SLD, similar results were also
- 268 observed. Remarkably, we found a powerful protect effect to cardiovascular mortality in
- 269 NAFLD+/MAFLD-/MASLD-/pure-MASLD- group (aHR: 0.02, 95% CI 0.00-0.18), but it was not
- 270 occurred in cancer mortality analysis (Table S10). As for the advanced fibrosis, similar results
- 271 were observed in intermediate and high NFS score groups (Table S11).
- 272 At last, we also conducted the subgroup analyses in this sensitivity analysis. Interestingly and
- 273 importantly, all the NALFD, MAFLD, MASLD and pure-MASLD were associated with increased
- all-cause mortality in female, age 41-55 years, non-Hispanic white and never smoking subgroups
- 275 (aHR: 1.19-1.61). Moreover, MAFLD and MASLD were associated with higher risk of all-cause
- 276 mortality in BMI 18.5-24.9 kg/m² and without diabetes subgroups (aHR: 1.18-1.52). (Figure 2B)

277

278 Discussion

- 279 As the new term of MASLD was proposed to replace NAFLD and MAFLD recently, we evaluated
- the clinical characteristics and mortality outcomes about these different terms in this longitudinal,
- 281 nationally representative, US population-based study. The main findings of our analysis were: 1)
- 282 MASLD can identify more individuals with risk of all-cause mortality than MAFLD, due to
- broader definition of metabolic risk factors; 2) pure-MASLD and NAFLD showed high
- 284 concordance in their clinical characteristics and outcomes, and both were not associated with all-
- cause mortality in total SLD individuals; 3) all the NAFLD, MAFLD, MASLD and pure-MASLD
- were associated with increased all-cause mortality in individuals with advanced fibrosis; 4) a

287 higher risk of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were also

- 288 observed in female, age 41-55 years, non-Hispanic white, and never smoking subgroups when
- 289 focused on moderate-severe hepatic steatosis.
- 290 Regarding to the relatively strict and complex of MAFLD definition ¹⁶, MASLD simplified the
- 291 number of metabolic risk factors, and relaxed the range of some criteria, such as the waist
- 292 circumference². Hence, MASLD will include more SLD individuals than MAFLD in theory, and
- this was proved by our result, that is, MASLD can identify about 3% more individuals than
- 294 MAFLD (29.04% vs. 26.13%). This phenomenon was also observed in a previous study from
- Hong Kong cohort (MASLD: 26.7% vs. MAFLD: 25.9%)⁵. Although several previous studies
- had assessed the association between MAFLD and all-cause mortality based on NHAENS III data
- ^{19 21-23}, the conclusions are still controversial, due to different adjusted models chose. Considering
- the possible pitfalls in the adjustment model choosing ²⁰, we just adjusted the sociodemographic
- characteristics and lifestyle risk factors of individuals, and any variable used in their definitions
- 300 were discarded. In this scenario, our result showed a significant higher risk of all-cause mortality
- in individuals with MAFLD, which was similar with a recent study using the same strategy ¹¹.
- 302 Importantly, we found that MASLD was also significantly associated with increased all-cause
- 303 mortality after adjustment. This result indicated that new term of MASLD is better identify people
- at risk of all-cause mortality than MAFLD. Because no study focused on the clinical outcome of
- 305 MASLD in a broad sense before, more studies are needed to verify the result.
- To better distinguish the effect of alcohol intake from MASLD, the Delphi consensus further
- 307 classified MASLD into pure-MASLD, MetALD, and MASLD with other etiologies. According to
- 308 the definition, individuals with excessive alcohol consumption were excluded from both pure-

309	MASLD and NAFLD, but pure-MASLD was restricted by the metabolic risk factors definition ²
310	¹⁵ . In this study, there were 10.1% individuals with NAFLD cannot be classified into pure-
311	MASLD. This was different with previous studies, which showed extremely high (over 99%)
312	accordance between NAFLD and pure-MASLD in cohorts from France ⁶ or Sweden ⁸ . This
313	discrepancy may be attributed to the differences of region, race, and enrollment time of
314	participants. As expected, all the individuals with pure-MASLD can be classified into NAFLD.
315	For the mortality outcomes, previous NHANES III based studies showed NAFLD per se was not
316	associated with increased risk of all-cause and cause-specific mortality, which were in line with
317	our result with a more extended follow-up period of the median 27 years ^{19 21 24} . Similarly, we
318	found that pure-MASLD was also not associated with all-cause mortality after adjustment, which
319	was in accordance with a recent study ¹⁰ . But Zhao et al. reported a higher risk of all-cause
320	mortality in individuals with pure-MASLD ¹¹ . This may due to more participants without alcohol
321	intake information were included in their study, which will result in some people who have no
322	information about alcohol consumption but indeed have excessive alcohol consumption being
323	classified into pure-MASLD group. Our results suggested that NAFLD and pure-MASLD were
324	highly similar in characteristics and clinical outcomes ⁹ , hence, old NAFLD data could still be
325	used and new biomarkers to differentiate NAFLD and pure-MASLD may be not needed.
326	Next, we evaluated the mortality among the different combinations of NAFLD, MAFLD, MASLD
327	and pure-MASLD. Due to other confounders of SLD, such as viral hepatitis and low BMI, has
328	been excluded in the main analysis, we can better to focus on the effect of metabolic risk factors
329	and alcohol intake on the outcomes of the four terms. Both NAFLD+/MAFLD+/MASLD+/pure-
330	MASLD+ and NAFLD-/MAFLD+/MASLD+/pure-MASLD- were associated with increased all-

331	cause mortality, and the later showed a larger effect. This indicated that metabolic dysregulation
332	met the criteria of MAFLD alone will increase the mortality risk, and excessive alcohol intake
333	plus metabolic dysregulation will further strengthen the risk of mortality, which was also observed
334	in previous study ¹⁹ . Interestingly, we found that NAFLD+/MAFLD-/MASLD+/pure-MASLD+,
335	but not NAFLD+/MAFLD-/MASLD-/pure-MASLD- was associated with lower risk of all-cause
336	and cause-specific mortality. This indicated that instead of no metabolic risk, only slight metabolic
337	risk (MAFLD-/MASLD+) was a protected effect to mortality in individuals with SLD. It is hard
338	for us to explain this odd result now, may be related to the small number of each group, and
339	studies with larger sample size are needed to clarify this. In addition, both NAFLD-/MAFLD-
340	/MASLD+/pure-MASLD- and NAFLD-/MAFLD-/MASLD-/pure-MASLD- were not associated
341	with all-cause and cause-specific mortality. This suggesting that excessive alcohol consumption
342	alone or plus slight metabolic risk will not increase the risk of mortality. Taken together, the
343	increased risk of mortality in SLD was only related to the extent of metabolic dysregulation, and
344	alcohol intake plays a boost role in this.
345	Except for metabolism and alcohol, fibrosis is another factor related to poor progress ²⁵ . Here, we
346	used the NFS score, as a surrogate index due to lack of the liver biopsy, to assess the possibility of
347	advanced fibrosis ¹⁷ . Previous study showed that advanced fibrosis in MAFLD, but not NAFLD,
348	was associated with a higher risk of all-cause mortality ¹⁹ . In our analysis, not only MAFLD, but
349	also NAFLD, MASLD and pure-MASLD were associated with increased all-cause mortality, and
350	the effects were larger with higher NFS score. Hence, even in the new term of MASLD,
351	individuals with advanced fibrosis are still a special population needed to pay more attention.
352	In subgroup analyses, we noticed that both MAFLD and MASLD were associated with increased

353	all-cause mortality in middle age (41-55 years) and non-Hispanic white subgroups. And both
354	NAFLD and pure-MASLD were not associated with all-cause mortality in any subgroup, which
355	was similar with a previous study on NAFLD ²⁴ . Notably, more powerful effects of all-cause-
356	mortality risk were observed among the four terms after excluding individuals with mild hepatic
357	steatosis from those with SLD. In this sensitivity analysis, individuals with NAFLD, MAFLD,
358	MASLD and pure-MASLD had higher risk of all-cause-mortality in female, middle age, non-
359	Hispanic white and never smoking subgroups. The reasons for these phenomena are complex and
360	unclear. For the age, we speculated the reason may be that the younger subgroup had a lower
361	mortality and the older subgroup had a higher mortality, which may counteract the effects of
362	NAFLD, MAFLD, MASLD and pure-MASLD. Similarly, we guessed that individuals with the
363	history of smoking (irrespective of previous or current smoking) had a higher mortality than never
364	smoking subgroup ²⁶ , which may weaken the discrepancy caused by NAFLD, MAFLD, MASLD
365	and pure-MASLD. But for sex and race, it is hard to confirm the specific cause now. The results in
366	subgroup analyses needed more studies to investigate and verify in future. All in all, subgroup and
367	sensitivity analyses showed the increased all-cause mortality among NAFLD, MAFLD, MASLD
368	and pure-MASLD were related to sex, age, race, smoking status and the extent of hepatic
369	steatosis.
370	Our study has some strengths. First, we comprehensively compared the clinical characteristics and
371	outcomes of NAFLD, MAFLD, MASLD and pure-MASLD using the NHANES III data, a large
372	nationally representative sample of the US population with a long follow-up period for mortality
373	(median of 27 years). Second, we conducted a strict screen strategy excluding individuals without
374	alcohol consumption information, or with other confounders (such as pregnancy, abnormal liver

375	enzymes levels, viral hepatitis, or BMI less than 18.5 kg/m ²), so that we can focus on the effect of
376	metabolic risk factors and alcohol intake on the mortality of these terms. Third, we first found that
377	the increased all-cause mortality among NAFLD, MAFLD, MASLD and pure-MASLD were
378	associated with sex, age, race, smoking status and the extent of hepatic steatosis in subgroup and
379	sensitivity analyses. Although the specific cause is unclear, more attention and earlier intervention
380	should be paid to these special populations in future.
381	Meanwhile, our study also has some limitations. First, due to the participants in NHANES III were
382	included between 1988-1994, the prevalence of NAFLD, MAFLD, MASLD and pure-MASLD
383	may not reflect the current extent. Second, due to the cross-sectional design of NHANES, we were
384	unable to assess dynamic changes in NAFLD, MAFLD, MASLD and pure-MASLD status over
385	time. Third, individuals with viral hepatitis or low BMI were added into the entire population in
386	sensitivity analysis, and similar results were observed. But considering the number of these
387	individuals were relatively small, the results should be interpreted with caution. Hence, the
388	specific effect of viral hepatitis on the mortality outcomes in SLD is still need to be verified in
389	studies with larger samples, especially in Asia and Africa where the prevalence of viral hepatitis
390	was high ²⁷ . Despite some of these limitations, we believe our findings are still important and
391	meaningful, benefited of a large population-based study using a nationally representative sample
392	and sufficient follow-up period.
393	In conclusion, the definition of MASLD was better than MAFLD to identify more individuals
394	with poor progress, whereas, pure-MASLD had similar characteristics and mortality outcomes
395	with NAFLD. The increased all-cause mortality of SLD was only associated with the extent of
396	metabolic dysfunction, but excessive alcohol intake will enlarge this effect. Moreover, higher risk

- 397 of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were also observed in
- individuals with advanced fibrosis and moderate-severe of hepatic steatosis, and in female, middle
- age, non-Hispanic white, and never smoking subgroups. Well-designed prospective studies with
- 400 larger samples are needed to verify our observations in future.
- 401 Acknowledgement
- 402 We gratefully acknowledge the contribution of the participants of the NHANES cohort, research
- 403 assistants, and facilitating personnel. And this work was supported by the first batch of key
- 404 disciplines on public health in Chongqing, Health Commission of Chongqing, China.
- 405 **Conflict of interest**
- 406 The authors declare no conflicts of interest.
- 407 Author contributions
- 408 Rui Song, Zhao Li and Yingzhi Zhang was involved in acquisition of data, data analysis and
- 409 interpretation, drafting of the manuscript, and study supervision. Jiahe Tan were involved in
- 410 interpretation of data and critical revision of the manuscript. Zhiwei Chen was involved in study
- 411 concept and design, interpretation of data, drafting of the manuscript, critical revision of the
- 412 manuscript, and study supervision. All authors contributed to the article and approved the
- 413 submitted version.
- 414 References
- 415 1. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden,
- 416 Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8(1):76-86.
- 417 2. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new
- 418 fatty liver disease nomenclature. J Hepatol 2023;S0168-8278(23)00418-X.

- 419 3. Sanal MG. NAFLD to MASLD is wokeism? J Hepatol 2023;S0168-8278(23)05081-X.
- 420 4. Emanuele E, Minoretti P. Letter to the Editor: NAFLD, MAFLD or MASLD? cut the Gordian
- 421 knot with "Ludwig disease". Hepatology 2023.
- 422 5. Song SJ, Che-To Lai J, Lai-Hung Wong G, et al. Can we use old NAFLD data under the new
- 423 MASLD definition? J Hepatol 2023;S0168-8278(23)05000-6.
- 424 6. Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed when
- transitioning from NAFLD to MASLD. J Hepatol 2023;S0168-8278(23)04996-6.
- 426 7. Chen L, Tao X, Zeng M, et al. Clinical and histological features under different nomenclatures
- 427 of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol 2023;S0168-
- 428 8278(23)05075-4.
- 429 8. Hagström H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria
- 430 and natural history is therefore identical. J Hepatol 2023;S0168-8278(23)05080-8.
- 431 9. Perazzo H, Pacheco AG, Griep RH. Changing from NAFLD trough MAFLD to MASLD:
- 432 similar prevalence and risk factors in a large Brazilian cohort. J Hepatol 2023;S0168-
- **433** 8278(23)05079-1.
- 434 10. Li M, Xie W. Are there all-cause mortality differences between metabolic dysfunction-
- 435 associated steatotic liver disease subtypes? J Hepatol 2023;S0168-8278(23)04989-9.
- 436 11. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or
- 437 MAFLD. J Hepatol 2023;S0168-8278(23)05055-9.
- 438 12. Chen VL, Song MW, Suresh D, et al. Effects of social determinants of health on mortality and
- 439 incident liver-related events and cardiovascular disease in steatotic liver disease. Aliment
- 440 Pharmacol Ther 2023;58(5):537-45.

- 441 13. National Center for Health Statistics CfDCaP. Analytic and reporting guidelines: The Third
- 442 National Health and Nutrition Examination Survey, NHANES III (1988-94) 1996 [Available from:
- 443 https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-
- 444 guidelines.pdf (Access on 2023.09.19).
- 14. III NHaNESN. Hepatic Steatosis Ultrasound Images Assessment Procedures Manual 2010
- 446 [Available from:
- 447 https://www.cdc.gov/nchs/data/nhanes/nhanes3/hepatic steatosis ultrasound procedures manual.
- 448 <u>pdf</u> (Asscess on 2023.09.19).
- 449 15. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet
- 450 2021;397(10290):2212-24.
- 451 16. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-
- 452 associated fatty liver disease: An international expert consensus statement. J Hepatol
- 453 2020;73(1):202-09.
- 454 17. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that
- identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
- 456 18. Statistics NCfH. 2019 Public-Use Linked Mortality Files 2022 [Available from:
- 457 <u>https://www.cdc.gov/nchs/data-linkage/mortality-public.htm</u> (Access on 2023.09.19).
- 458 19. Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is
- 459 associated with increased all-cause mortality in the United States. J Hepatol 2021;75(6):1284-91.
- 460 20. Attia D, Gomaa A, Abdel Alem S. Letter to the editor: Pitfalls in the outcome differences
- 461 between NAFLD and MAFLD. Hepatology 2022;76(5):E100.
- 462 21. Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD

- and metabolic-associated fatty liver disease? Hepatology 2022;76(5):1423-37.
- 464 22. van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease
- and excessive alcohol consumption are both independent risk factors for mortality. Hepatology
- 466 2023;77(3):942-48.
- 467 23. Huang Q, Zou X, Wen X, et al. NAFLD or MAFLD: Which Has Closer Association With All-
- 468 Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne)
- 469 2021;8:693507.
- 470 24. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among
- 471 US adults: prospective cohort study. Bmj 2011;343:d6891.
- 472 25. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A
- 473 Review. Jama 2023;329(18):1589-602.
- 474 26. Cunha ARD, Compton K, Xu R, et al. The Global, Regional, and National Burden of Adult
- 475 Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the
- 476 Global Burden of Disease Study 2019. JAMA Oncol 2023;e232960.
- 477 27. Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J
- 478 Hepatol 2023;79(2):516-37.
- 479
- 480
- 481
- 482
- 483
- 484

485 Figure and Figure Legends





23

Α								
Subgroups	NAFLD	Adjusted HR	MAFLD	Adjusted HR	MASLD	Adjusted HR	Pure-MASLD	Adjusted HR
Sex								
male	⊢ _ →	1.05	⊢∎→	1.10	⊷ -	1.06	⊢ ∎	1.02
female	⊢∎→	1.11		1.39	⊷ ∎	1.17	·	1.14
Age (years)								
20-40		0.77		0.95		0.86		0.79
41-55		123		1.57		1.37		1.26
> 56		1.00		1.02		1 11		1.11
≥ 50 Pace or ethnicity		1.00		1.20				1.11
Nee bissesis white		1 10			_			
Non-hispanic white		1.10	H -	1.26		1.12		1.10
Non-hispanic black	+- -	1.03		1.15	+	1.15		1.03
Mexican-American	⊢ ∎-+	0.83	H 	0.90	H B H	0.91	⊢ ∎→	0.84
Others	· · · · · · · · · · · · · · · · · · ·	0.87	-	1.10	· · · · · · · · · · · · · · · · · · ·	1.01		0.89
BMI (kg/m²)								
18.5-24.9		0.98		1.57		0.92		0.92
25-29.9		1.09		1.09		1.09		1.09
30-34.9	- -	0.79		0.87		0.87		0.79
> 35		1 16		1.53		1.53		1 16
Diabotos	. –			- 1.55	. –	1.00	· -	
Ne		1.02					. L.	
INU X		1.03	_ [-	1.10		1.06		1.02
Yes		0.79		0.83		0.83		0.79
Hypertension								
No	- -	0.95	⊢∎⊸I	1.14	- -	0.97	⊷∎⊷	0.92
Yes		1.15	⊢ ∎-1	1.14	⊢ ∎→	1.15		1.15
Smoking status								
Never		1.13		1.16		1.10	⊢∎⊸	1.11
Past smoker		1.08		1.10		1.10	⊢ ∎−−→	1.06
Current smoker		0.96		1.37		1.12		0.99
	· · · · · ·		· · · · ·				· · · · ·	
B Subgroups	NAFLD	Adjusted HR	MAFLD	Adjusted HR	MASLD	Adjusted HR	Pure-MASLD	Adjusted HR
B Subgroups Sex	NAFLD	Adjusted HR	MAFLD	Adjusted HR	MASLD	Adjusted HR	Pure-MASLD	Adjusted HR
B Subgroups Sex male		Adjusted HR	MAFLD	Adjusted HR	MASLD	Adjusted HR	Pure-MASLD	Adjusted HR
B Subgroups Sex male female		Adjusted HR 1.08 1.28		Adjusted HR 1.17 1.37	MASLD	Adjusted HR 1.17 1.34	Pure-MASLD	Adjusted HR 1.10 1.30
B Subgroups Sex male female Age (years)	NAFLD	Adjusted HR 1.08 1.28	MAFLD	Adjusted HR 1.17 1.37	MASLD	Adjusted HR 1.17 1.34	Pure-MASLD	Adjusted HR 1.10 1.30
B Subgroups Sex male female Age (years) 20-40	NAFLD	Adjusted HR 1.08 1.28 0.86		Adjusted HR 1.17 1.37 1.15	MASLD	Adjusted HR 1.17 1.34 1.09	Pure-MASLD	Adjusted HR 1.10 1.30 0.91
B Subgroups Sex male female Age (years) 20-40 41 55		Adjusted HR 1.08 1.28 0.86 1.49		Adjusted HR 1.17 1.37 1.15 1.61	MASLD	Adjusted HR 1.17 1.34 1.09 1.60	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53
B Subgroups Sex male female Age (years) 20-40 41-55		Adjusted HR 1.08 1.28 0.86 1.49 1.07	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Brace as at blais it.		Adjusted HR 1.08 1.28 0.86 1.49 1.07	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity		Adjusted HR 1.08 1.28 0.86 1.49 1.07	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10
B Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white		Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28	MASLD	Adjusted HR 1.17 1.34 1.60 1.16 1.26	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21
B Sex male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black		Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American		Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic Mack Mexican-American Others		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 .086 .086	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10
B Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Nor-hispanic white Nor-hispanic white Mexican-American Others BMI (kg/m²)	NAFLD	Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 1.26 1.16 0.98 	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American Others BMI (kg/m³) 18.5-24.9	NAFLD	Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.06 1.18	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 0.98 1.37 1.35	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.24
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9		Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.16 1.18 1.10	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 1.37 1.35 1.14	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Non-hispanic white Non-hispanic white Non-hispanic black Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9	NAFLD	Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 .1.39 1.52 1.14 0.91	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 1.37 1.35 1.14 0.91	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.21 1.06 0.91 1.21 1.06 0.91 1.21 1.00 0.91 0.91 1.30 0.91 0.93 0.91 0.93 0.94
B Subgroups Sex male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 ≥ 35	NAFLD	Adjusted HR 1.08 1.28 0.96 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.48	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.55	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 1.26 1.16 0.98 	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48
B Subgroups Sex male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American Others BMI (kg/m²) 18.5-24.9 25-29.9 30-34.9 ≥ 35 Diabates	NAFLD	Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.10 0.82	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 0.98 1.37 1.35 1.14 0.91 1.56	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic White Non-hispanic White Non-hispanic White Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 ≥ 35 Diabetes No		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.10 0.82 1.14	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.19	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.88 1.37 1.35 1.14 0.91 1.56	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13
B Subservestions Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Non-hispanic white Non-hispanic white Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 ≥ 55 Diabetes No Xo		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.10 1.18 1.10 0.82 1.48 1.11 0.82	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.97	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 1.37 1.35 1.14 0.91 1.56 1.18 0.97	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.24 1.06 0.91 1.34 1.10 0.82 1.48 1.13 0.82
B Subgroups Sex male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Non-hispanic white Non-hispanic white BMI (kg/m²) 18.5-24.9 25-29.9 30-34.9 ≥ 35 Diabetes No Yes	NAFLD	Adjusted HR 1.08 1.28 0.96 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.11 0.81	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 1.26 1.16 0.98 1.37 1.35 1.14 0.91 0.91 1.56 1.18 0.87	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13 0.81
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 30-34.9	NAFLD	Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.62 1.18 1.11 0.81 1.11 0.81	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 0.98 1.37 1.35 1.14 0.91 1.56 1.18 0.87	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13 0.81
B Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic White Non-hispanic Mack Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 ≥ 35 Diabetes No Yes Hypertension No		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.11 0.81 1.11 0.81 1.10	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.55 1.18 0.87 1.26	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.88 1.37 1.35 1.14 0.91 1.56 1.18 0.87 1.23	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.24 1.06 0.91 1.24 1.06 0.91 1.48 1.13 0.81 1.14
B Susy male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Non-hispanic white Non-hispanic white Non-hispanic white Macican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-35 25-29.9 30-35 25-29.9 30-35 25-35		Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.11 0.81 1.11 0.81 1.10 1.16	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87 1.26 1.13	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 1.26 1.16 1.37 1.35 1.14 0.91 1.56 1.18 0.87 1.18 0.87 1.15	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13 0.81 1.14 1.14 1.16
B Subgroups Sex male female 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic black Moxican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 30-35 25-29.9 30-35	NAFLD	Adjusted HR 1.08 1.28 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.48 1.11 0.81 1.10 1.16	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87 1.26 1.13	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 0.98 1.37 1.35 1.14 0.91 1.56 1.18 0.87 1.23 1.15	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13 0.81 1.14 1.16
B Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic White Non-hispanic White Non-hispanic White Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 ≥ 35 Diabetes No Yes Hypertension No Yes Smoking status Never		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.48 1.11 0.81 1.10 1.16 1.16 1.26	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87 1.26 1.13 1.34	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.88 1.37 1.35 1.14 0.91 1.56 1.14 0.91 1.56 1.18 0.87 1.23 1.15 1.23 1.15	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.24 1.06 1.34 1.10 0.82 1.48 1.13 0.81 1.14 1.16
B Subgroups Sex male female Age (years) 20-40 41-55 2 56 Race or ethnicity Non-hispanic white Non-hispanic white Non-hispanic black Mexican-American Others BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 2 35 Diabetes No Yes Since Since		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.11 0.81 1.11 0.81 1.10 1.16 1.26 1.26 1.03	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.55 1.18 0.87 1.26 1.13 1.34 1.06	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.16 1.26 1.16 0.98 1.37 1.35 1.14 0.91 1.56 1.18 0.87 1.23 1.15 1.13 1.13 1.13	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.24 1.06 0.91 1.54 1.04 1.10 1.34 1.13 0.81 1.14 1.14 1.16 1.31 1.04
B Subgroups Sex male female Age (years) 20-40 41-55 ≥ 56 Race or ethnicity Non-hispanic white Non-hispanic white BMI (kg/m ²) 18.5-24.9 25-29.9 30-34.9 30-34		Adjusted HR 1.08 1.23 0.86 1.49 1.07 1.19 1.06 0.86 1.18 1.10 0.82 1.18 1.11 0.81 1.11 0.81 1.10 1.16 1.26 1.03 1.12	MAFLD	Adjusted HR 1.17 1.37 1.15 1.61 1.19 1.28 1.08 0.94 1.39 1.52 1.14 0.91 1.56 1.18 0.87 1.26 1.13 1.34 1.06 1.31	MASLD	Adjusted HR 1.17 1.34 1.09 1.60 1.16 1.26 1.16 0.98 1.37 1.35 1.14 0.91 1.56 1.18 0.87 1.15 1.18 1.15 1.13 1.15 1.13 1.15 1.13 1.15 1.13 1.13	Pure-MASLD	Adjusted HR 1.10 1.30 0.91 1.53 1.10 1.21 1.06 0.91 1.10 1.34 1.10 0.82 1.48 1.13 0.81 1.14 1.14 1.54 1.31 1.14 1.31 1.04 1.24



499 Figure 2. Subgroup analyses of association with all-cause mortality among NAFLD,

500 MAFLD, MASLD and pure-MASLD in total SLD individuals (A) and in moderate-severe

SLD individuals (B). Green box means HR value without statistical difference. Red box means 501

- HR value with statistical difference. The bars on both sides of box mean 95% CI of HR. The 502
- adjusted model 2 (sex, age, race/ethnicity, marital status, education, sedentary lifestyle, and 503
- smoking status) was used in this analysis. BMI, body mass index; CI, confidence intervals. HR, 504

- 505 hazard ratio; SLD, steatotic liver disease; MAFLD, dysfunction-associated fatty liver disease;
- 506 MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty
- 507 liver disease metabolic.

Characteristics	No hepatic steatosis (n=4,544)	Group 1# (n=1,575)	Group 2# (n=178)	Group 3# (n=166)	Group 4# (n=196)	Group 5 [#] (n=29)	Group 6 [#] (n=20)	Р
Age (years)	36.0 (28.0, 48.0)	47.0 (36.0, 60.0)	47.0 (35.0, 58.9)	32.0 (26.0, 44.0)	30.0 (25.0, 39.0)	37.0 (29.3, 62.0)	30.0 (27.2, 31.5)	< 0.001
Sex (male)	2,301 (52%)	773 (56%)	135 (76%)	57 (30%)	86 (41%)	23 (76%)	15 (69%)	< 0.001
Race/ethnicity								0.10
Non-Hispanic white	1,814 (78%)	597 (75%)	76 (86%)	75 (83%)	80 (82%)	12 (81%)	9 (83%)	
Non-Hispanic black	1,198 (4.5%)	560 (6.3%)	62 (5.1%)	43 (3.5%)	50 (4.7%)	8 (5.3%)	2 (1.2%)	
Mexican-American	1,324 (9.8%)	348 (8.2%)	36 (6.3%)	40 (7.8%)	61 (8.4%)	9 (13%)	8 (8.7%)	
Others	208 (8.1%)	70 (10%)	4 (2.9%)	8 (5.9%)	5 (4.4%)	0 (0%)	1 (7.0%)	
Body mass index (kg/m ²)	24.6 (22.3, 27.3)	29.3 (26.5, 32.4)	28.3 (25.9, 32.2)	22.0 (20.9, 23.7)	21.7 (20.4, 22.9)	22.7 (20.6, 24.1)	21.2 (19.7, 21.9)	< 0.001
Waist circumference (cm)	88 (79, 96)	102 (94, 110)	100 (91, 110)	81 (73, 85)	74 (70, 79)	84 (81, 91)	75 (70, 79)	< 0.001
≥12 years education	3,094 (82%)	874 (73%)	106 (78%)	111 (82%)	138 (81%)	18 (86%)	12 (61%)	< 0.001
Marital status	2,798 (65%)	1,097 (75%)	117 (64%)	101 (62%)	117 (73%)	17 (81%)	10 (63%)	< 0.001
Hypertension	1,140 (20%)	691 (43%)	105 (67%)	22 (8.9%)	5 (2.7%)	9 (28%)	2 (10%)	< 0.001
Diabetes	219 (2.8%)	298 (13%)	25 (9.1%)	1 (0.8%)	0 (0%)	0 (0%)	0 (0%)	< 0.001
Smoking status								< 0.001
Never	2,297 (46%)	826 (48%)	41 (30%)	91 (49%)	111 (57%)	6 (11%)	5 (15%)	
Past smoker	866 (22%)	427 (30%)	64 (37%)	24 (15%)	22 (14%)	6 (23%)	2 (16%)	
Current smoker	1,381 (32%)	322 (22%)	73 (33%)	51 (36%)	63 (29%)	17 (66%)	13 (68%)	
Alcohol consumption (g/d)	4 (1, 12)	2 (0, 8)	42 (36, 60)	3 (1, 6)	4 (1, 12)	48 (32, 56)	61 (36, 82)	< 0.001
Sedentary lifestyle	1,061 (16%)	520 (24%)	42 (16%)	41 (17%)	37 (9.5%)	9 (28%)	6 (42%)	< 0.001
Triglycerides (mg/dL)	1.1 (0.8, 1.6)	1.8 (1.2, 2.6)	1.6 (1.2, 2.3)	1.0 (0.8, 1.3)	0.9 (0.7, 1.2)	0.8 (0.7, 1.1)	0.7 (0.5, 1.1)	< 0.001
HDL-cholesterol (mg/dL)	1.3 (1.1, 1.6)	1.1 (0.9, 1.3)	1.3 (1.0, 1.5)	1.3 (1.1, 1.5)	1.6 (1.3, 1.8)	1.5 (1.3, 1.8)	1.9 (1.3, 2.3)	< 0.001

Table 1.	Baseline	characteristics	of the study	population	(N = 6)	,708).
					(-· · ·	,,

C-reactive protein (mg/dL)	0.2 (0.2, 0.2)	0.2 (0.2, 0.5)	0.2 (0.2, 0.4)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2) <0.001
Glucose (mol/L)	5.1 (4.8, 5.4)	5.4 (5.0, 5.8)	5.3 (4.9, 5.6)	5.0 (4.7, 5.3)	4.9 (4.7, 5.2)	5.2 (4.9, 5.5)	5.0 (4.5, 5.6) <0.001
Insulin (uU/mL)	7.0 (5.4, 9.7)	11.4 (8.3, 15.9)	9.6 (7.1, 13.6)	7.1 (5.1, 8.5)	5.6 (4.7, 7.4)	5.3 (4.1, 6.9)	4.2 (4.2, 5.4) <0.001
Hemoglobin A1c (%)	5.1 (4.8, 5.4)	5.4 (5.0, 5.7)	5.2 (5.0, 5.5)	5.1 (4.8, 5.3)	5.0 (4.6, 5.3)	5.0 (4.5, 5.3)	5.1 (4.7, 5.1) <0.001
HOMA-IR	1.6 (1.2, 2.3)	2.8 (2.0, 4.2)	2.2 (1.6, 3.3)	1.5 (1.1, 1.9)	1.2 (1.0, 1.7)	1.2 (1.0, 1.5)	1.1 (0.9, 1.3) <0.001

Data are shown as the median (interquartile range) or unweighted frequency counts (weighted percentage) as appropriate. The Kruskal-Wallis test for continuous variables and the Chi-square test for categorical variables were used in this analysis.

[#] Group 1, NAFLD+/MAFLD+/MASLD+/pure-MASLD+; Group 2, NAFLD+/MAFLD-/MASLD+/pure-MASLD+; Group 3, NAFLD-/MAFLD+/MASLD+/pure-MASLD-; Group 4, NAFLD-/MAFLD-/MASLD-/pure-MASLD-; Group 5, NAFLD-/MAFLD-/MAFLD-/MASLD+/pure-MASLD-; Group 6, NAFLD-/MAFLD-/MAFLD-/MASLD-/pure-MASLD-; Group 6, NAFLD-/MAFLD-/MAFLD-/MASLD-/pure-MASLD-; Group 6, NAFLD-/MAFLD-/MAFLD-/MASLD-/pure-MASLD-; Group 6, NAFLD-/MA

HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

				NI	n	Univariable 1	nodel	Multivariable M	lodel 1	Multivariable N	Model 2
				IN	(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
No SLD				4,544	1,244	1		1		1	
SLD				2,164	817	1.61 (1.43-1.80)	< 0.001	1.13 (1.01-1.27)	0.039	1.12 (1.00-1.25)	0.046
No NAFI	D			4,771	1,348	1		1		1	
NAFLD				1,937	713	1.5 (1.32-1.70)	< 0.001	1.07 (0.95-1.20)	0.3	1.07 (0.95-1.20)	0.2
No MAFI	LD			4,958	1309	1		1		1	
MAFLD				1,753	752	2.1 (1.86-2.36)	< 0.001	1.19 (1.07-1.34)	0.002	1.21 (1.09-1.35	< 0.001
No MASI	LD			4,760	1,269	1		1		1	
MASLD				1,948	792	1.85 (1.67-2.05)	< 0.001	1.13 (1.01-1.26)	0.032	1.11 (1.00-1.23)	0.048
No pure-l	MASLD			4,967	1,368	1		1		1	
Pure-MA	SLD			1,741	693	1.72 (1.51-1.96)	< 0.001	1.07 (0.96-1.20)	0.2	1.07 (0.96-1.19)	0.3
No hepati	c steatosis			4,544	1,244	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,575	665	1.97 (1.73-2.25)	< 0.001	1.15 (1.03-1.29)	0.017	1.17 (1.05-1.30)	0.006
-	+	+	-	178	87	2.25 (1.56-3.25)	< 0.001	1.42 (1.03-1.96)	0.035	1.34 (1.02-1.77)	0.036
+	-	+	+	166	28	0.45 (0.27-0.77)	0.003	0.52 (0.34-0.80)	0.003	0.42 (0.24-0.73)	0.002
+	-	-	-	196	20	0.49 (0.27-0.89)	0.02	1.03 (0.65-1.64)	>0.9	1.13 (0.72-1.77)	0.6
-	-	+	-	29	12	1.99 (0.81-4.90)	0.13	1.33 (0.61-2.93)	0.5	1.01 (0.35-2.89)	>0.9
-	-	-	-	20	5	0.65 (0.16-2.74)	0.6	2.41 (0.68-8.56)	0.2	1.61 (0.45-5.78)	0.5

Table 2. Association among NAFLD, MAFLD, MASLD and pure-MASLD status, and all-cause mortality.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; SLD, steatosis liver disease; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunctionassociated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

			,	,	n	n Univariable model		Multivariable Mo	del 1	Multivariable Mo	Multivariable Model 2		
				Ν	(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р		
Cardiova	scular mor	tality											
No NAFL	D			4,771	347	1		1		1			
NAFLD				1,937	190	1.43 (1.07-1.93)	0.017	0.97 (0.73-1.29)	0.8	0.96 (0.71-1.30)	0.8		
No MAFI	LD			4,958	332	1		1		1			
MAFLD				1,753	205	2.23 (1.71-2.91)	< 0.001	1.19 (0.92-1.53)	0.2	1.21 (0.94-1.57	0.14		
No MASI	D			4,760	324	1		1		1			
MASLD				1,948	213	1.90 (1.44-2.49)	< 0.001	1.08 (0.83-1.42)	0.5	1.06 (0.81-1.40)	0.7		
No pure-M	MASLD			4,967	350	1		1		1			
Pure-MAS	SLD			1,741	187	1.74 (1.31-2.30)	< 0.001	1.01 (0.76-1.35)	>0.9	1.00 (0.74-1.36)	>0.9		
No hepati	c steatosis			4,544	319	1		1		1			
NAFLD	MAFLD	MASLD	pure-MASLD										
+	+	+	+	1,575	182	2.02 (1.52-2.67)	< 0.001	1.1 (0.83- 1.46)	0.5	1.12 (0.84, 1.48)	0.4		
-	+	+	-	178	23	2.53 (1.37-4.67)	0.003	1.55 (0.79- 3.04)	0.2	1.47 (0.79, 2.74)	0.2		
+	-	+	+	166	5	0.20 (0.04-0.96)	0.015	0.23 (0.05-1.07)	0.06	0.17 (0.03, 0.83)	0.029		
+	-	-	-	196	3	0.11 (0.02-0.67)	0.016	0.27 (0.04- 1.70)	0.2	0.31 (0.06, 1.69)	0.2		
-	-	+	-	29	3	1.20 (0.27-5.34)	0.8	0.71 (0.14-3.71)	0.7	0.63 (0.13, 3.11)	0.6		
-	-	-	-	20	2	1.53 (0.22-10.80)	0.7	8 (1.44- 44.4)	0.017	4.99 (0.88, 28.2)	0.069		
Cancer m	ortality												
No NAFL	D			4,771	358	1		1		1			
NAFLD				1,937	165	1.27 (0.93, 1.74)	0.14	0.94 (0.69, 1.29)	0.7	0.99 (0.72, 1.36)	>0.9		
No MAFI	LD			4,958	348	1		1		1			
MAFLD				1,753	175	1.89 (1.46, 2.45)	< 0.001	1.13 (0.86, 1.48)	0.4	1.21 (0.92, 1.60)	0.2		
No MASI	LD			4,760	337	1		1		1			

Table 3 Association among NAFLD	MAFLD MASLD and	nure-MASLD status	and cardiovascular	disease and cancer-rele	ated mortality
Table 5. Association among MATLD	, MATLD, MASLD and	purc-masin status,	and cardiovascular	uiscase and cancel-leia	aleu mortanty.

MASLD				1,948	186	1.63 (1.29, 2.07)	< 0.001	1.04 (0.80, 1.35)	0.8	1.07 (0.83, 1.39)	0.6
No pure-N	MASLD			4,967	363	1		1		1	
Pure-MA	SLD			1,741	160	1.44 (1.07, 1.94)	0.016	0.94 (0.70, 1.27)	0.7	0.98 (0.73, 1.33)	>0.9
No hepati	c steatosis			4,544	331	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,575	152	1.69 (1.24- 2.32)	0.001	1.04 (0.76- 1.41)	0.8	1.11 (0.81- 1.52)	0.5
-	+	+	-	178	23	2.59 (1.44- 4.67)	0.001	1.63 (0.92-2.87)	0.092	1.61 (0.93- 2.78)	0.09
+	-	+	+	166	8	0.26 (0.10- 0.64)	0.004	0.3 (0.12- 0.77)	0.012	0.22 (0.07- 0.64)	0.006
+	-	-	-	196	5	0.52 (0.15- 1.75)	0.3	0.99 (0.30- 3.26)	>0.9	1.07 (0.31- 3.66)	>0.9
-	-	+	-	29	3	1.69 (0.39- 7.27)	0.5	1.19 (0.23- 6.09)	0.8	0.8 (0.14-4.47)	0.8
-	-	-	-	20	1	0.74 (0.09- 6.32)	0.8	1.87 (0.23-15.1)	0.6	1.21 (0.14-10.2)	0.9

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

	NI	n	Univariable mo	del	Multivariable Mo	del 1	Multivariable Mo	del 2
	N	(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
NAFLD								
Low NFS	1,277	294	1		1		1	
Intermediate NFS	545	331	4.07 (3.18, 5.21)	< 0.001	1.24 (1.00, 1.53)	0.048	1.27 (1.04, 1.55)	0.02
High NFS	97	79	6.98 (4.44, 11.0)	< 0.001	1.87 (1.25, 2.80)	0.002	1.79 (1.24, 2.60)	0.002
MAFLD								
Low NFS	1,064	299	1		1		1	
Intermediate NFS	570	359	3.74 (2.90, 4.81)	< 0.001	1.45 (1.16, 1.80)	0.001	1.53 (1.24, 1.89)	< 0.001
High NFS	103	85	6.35 (4.16, 9.68)	< 0.001	1.93 (1.32, 2.81)	< 0.001	1.83 (1.29, 2.59)	< 0.001
MASLD								
Low NFS	1,227	323	1		1		1	
Intermediate NFS	595	373	3.9 (3.04, 5.00)	< 0.001	1.38 (1.12, 1.70)	0.003	1.41 (1.15, 1.72)	< 0.001
High NFS	106	86	6.34 (4.15, 9.69)	< 0.001	1.81 (1.25, 2.63)	0.002	1.66 (1.14, 2.42)	0.008
Pure-MASLD								
Low NFS	1,097	280	1		1		1	
Intermediate NFS	532	327	3.79 (3.00, 4.81)	< 0.001	1.28 (1.03, 1.58)	0.027	1.31 (1.06, 1.62)	0.011
High NFS	95	78	6.73 (4.28, 10.6)	< 0.001	1.88 (1.22, 2.91)	0.005	1.8 (1.20, 2.69)	0.004

Table 4. Association of advanced fibrosis status and all-cause mortality among individuals with NAFLD, MAFLD, MASLD and pure-MASLD.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic; NFS, NAFLD fibrosis score.

Table 5. Association among NAFLD, MAFLD, MASLD and pure-MASLD status, and all-cause mortality in individuals with moderate-severe hepatic steatosis[#].

				N	n	Univariable r	nodel	Multivariable N	Model 1	Multivariable N	Iodel 2
				1	(deaths)	HR (95% CI)	Р	HR (95% CI)	Р	HR (95% CI)	Р
No NAFL	D			4,682	1,319	1		1		1	
NAFLD				1,155	491	1.96 (1.70, 2.26)	< 0.001	1.15 (1.04, 1.28)	0.006	1.16 (1.04, 1.30)	0.01
No MAFI	LD			4,700	1,281	1		1		1	
MAFLD				1,137	529	2.39 (2.14, 2.68)	< 0.001	1.25 (1.12, 1.39)	< 0.001	1.25 (1.13, 1.39)	< 0.001
No MASI	LD			4,614	1,251	1		1		1	
MASLD				1,223	559	2.26 (2.01, 2.55)	< 0.001	1.25 (1.13, 1.39)	< 0.001	1.24 (1.12, 1.38)	< 0.001
No pure-M	MASLD			4,745	1324	1		1		1	
Pure-MAS	SLD			1,092	486	2.08 (1.81, 2.40)	< 0.001	1.18 (1.06, 1.31)	0.003	1.18 (1.05, 1.33)	0.005
No hepati	c steatosis			4,544	1,244	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,022	466	2.31 (2.04, 2.63)	< 0.001	1.22 (1.10, 1.36)	< 0.001	1.23 (1.10, 1.38)	< 0.001
-	+	+	-	115	63	2.89 (1.88, 4.46)	< 0.001	1.49 (1.07, 2.07)	0.018	1.39 (1.06, 1.83)	0.019
+	-	+	+	70	20	0.77 (0.35, 1.67)	0.5	0.89 (0.60, 1.31)	0.5	0.8 (0.44, 1.42)	0.4
+	-	-	-	63	5	0.29 (0.09, 0.97)	0.045	0.43 (0.15, 1.24)	0.12	0.48 (0.21, 1.10)	0.083
-	-	+	-	16	10	3.97 (1.66, 9.51)	0.002	2.56 (1.28, 5.11)	0.008	2.65 (1.70, 4.12)	< 0.001
-	-	-	-	7	2	0.66 (0.08, 5.38)	0.7	2.03 (0.32, 12.9)	0.5	1.26 (0.20, 8.02)	0.8

 $^{\#}$ (n=5,837) excluding individuals with mild hepatic steatosis from the SLD.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; SLD, steatosis liver disease; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunctionassociated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.